Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Payables: 2013-2025

Historic Payables for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $190.8 million.

  • Amphastar Pharmaceuticals' Payables rose 24.52% to $190.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $690.4 million, marking a year-over-year increase of 39.60%. This contributed to the annual value of $157.1 million for FY2024, which is 68.22% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Payables of $190.8 million as of Q3 2025, which was up 14.59% from $166.6 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Payables registered a high of $222.7 million during Q3 2023, and its lowest value of $84.2 million during Q4 2022.
  • Moreover, its 3-year median value for Payables was $157.1 million (2024), whereas its average is $155.8 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Payables skyrocketed by 132.49% in 2023 and then slumped by 39.68% in 2024.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Payables stood at $89.5 million in 2021, then declined by 5.92% to $84.2 million in 2022, then grew by 10.83% to $93.4 million in 2023, then surged by 68.22% to $157.1 million in 2024, then increased by 24.52% to $190.8 million in 2025.
  • Its Payables was $190.8 million in Q3 2025, compared to $166.6 million in Q2 2025 and $175.9 million in Q1 2025.